Scarica l'app Stockscreener
16.06
0.86%
-0.14
Pre-mercato:
16.10
0.04
+0.25%
Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie
Heatmap analysis for Syndax Pharmaceuticals Inc. and competitors2025 Market Outlook & Community Verified Trade Alerts - newser.com
Evaluating Syndax Pharmaceuticals Inc. with trendline analysis2025 Pullback Review & Reliable Price Breakout Alerts - newser.com
Will Syndax Pharmaceuticals Inc. stock see insider buying2025 EndofYear Setup & Verified Chart Pattern Signals - newser.com
Published on: 2025-10-10 04:00:50 - newser.com
Menin Inhibitors Drug Market Report 2025: Price, Sales & Clinical Trials Insights 2024-2028 - GlobeNewswire Inc.
Order flow analysis tools used on Syndax Pharmaceuticals Inc.2025 Retail Activity & Fast Gain Swing Trade Alerts - newser.com
Syndax resumed with Buy at Stifel on newly launched drugs - MSN
Analyzing drawdowns of Syndax Pharmaceuticals Inc. with statistical toolsPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Published on: 2025-10-09 05:04:06 - newser.com
Should you hold or exit Syndax Pharmaceuticals Inc. nowJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Is Syndax Pharmaceuticals Inc 1T3 a good long term investmentValue Traps to Avoid & Small Investment Portfolio - earlytimes.in
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - AOL.com
Technical analysis overview for Syndax Pharmaceuticals Inc. stockJuly 2025 Trends & AI Driven Price Forecasts - newser.com
Research Analysts Offer Predictions for SNDX FY2027 Earnings - MarketBeat
Will October's FDA Decision Be A Shot In The Arm For Revuforj's Expansion? - RTTNews
Is Syndax Pharmaceuticals Inc. (1T3) stock considered safe havenJuly 2025 Rallies & Short-Term High Return Strategies - newser.com
Measuring Syndax Pharmaceuticals Inc.’s beta against major indices2025 Geopolitical Influence & Reliable Volume Spike Alerts - newser.com
Comparing Syndax Pharmaceuticals Inc. in custom built stock radarsProduct Launch & Real-Time Volume Analysis Alerts - newser.com
Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision - Yahoo
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
BRIEF-Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule - The Sunday Guardian
Syndax Pharmaceuticals reports inducement grants under Nasdaq Listing Rule - MarketScreener
Does Syndax Pharmaceuticals Inc. qualify in momentum factor screeningStop Loss & Daily Entry Point Trade Alerts - newser.com
138,900-Share Grant: Syndax Awards to 10 New Employees; Options Vest Monthly Under Inducement Plan - Stock Titan
Regulatory Milestone and Analyst Optimism Fuel Momentum for Syndax Pharmaceuticals - MSN
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
What analysts say about Syndax Pharmaceuticals Inc stockEarnings Revision Updates & Minimize Portfolio Damage with Warnings - earlytimes.in
When Will Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Turn A Profit? - Yahoo Finance
Syndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from BTIG Research - MarketBeat
Risk On: Can Syndax Pharmaceuticals Inc stock double in the next yearGap Down & Real-Time Buy Zone Alerts - خودرو بانک
Multiple Insiders Sold Syndax Pharmaceuticals Shares Presenting Weak Signs For Investors - 富途牛牛
Syndax Pharmaceuticals Nears Critical Regulatory Milestone - AD HOC NEWS
Highs Report: What’s next for IRIDEX Corporation stockBreakout Watch & Daily Profit Focused Stock Screening - khodrobank.com
Update Recap: Can CZWI disrupt its industryEarnings Recap Report & Verified Entry Point Signals - khodrobank.com
BTIG Reiterates Buy Rating on SNDX with $56 Price Target | SNDX Stock News - GuruFocus
3 Potential Biotech Acquisition Targets - Seeking Alpha
SNDX: Revumenib Gains Key NCCN Recommendation for AML Treatment - GuruFocus
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia - The Manila Times
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):